Search Results - "Portal, Daniella E."

Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies by Groisberg, Roman, Roszik, Jason, Conley, Anthony P, Lazar, Alexander J, Portal, Daniella E, Hong, David S, Naing, Aung, Herzog, Cynthia E, Somaiah, Neeta, Zarzour, Maria A, Patel, Shreyaskumar, Brown, Robert E, Subbiah, Vivek

“…Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment…”
Get full text

Combination drug regimens for metastatic clear cell renal cell carcinoma by Khetani, Viraj V, Portal, Daniella E, Shah, Mansi R, Mayer, Tina, Singer, Eric A

“…Renal cell carcinomas (RCC) make up about 90% of kidney cancers, of which 80% are of the clear cell subtype. About 20% of patients are already metastatic at…”
Get full text

A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850 by Spencer, Kristen R, Portal, Daniella E, Aisner, Joseph, Stein, Mark N, Malhotra, Jyoti, Shih, Weichung, Chan, Nancy, Silk, Ann W, Ganesan, Shridar, Goodin, Susan, Gounder, Murugesan, Lin, Hongxia, Li, Jiadong, Cerchio, Robert, Marinaro, Christina, Chen, Suzie, Mehnert, Janice M

“…Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate…”
Get full text

The human microbiome and genitourinary malignancies by Nicolaro, Michael, Portal, Daniella E., Shinder, Brian, Patel, Hiren V., Singer, Eric A.

“…The human microbiome contains a vast network of understudied organisms that have an intimate role in our health and wellness. These microbiomes differ greatly…”
Get full text

Validation of a claims‐based algorithm for identifying non‐infectious pneumonitis in patients diagnosed with lung cancer by Neibart, Shane S., Portal, Daniella E., Malhotra, Jyoti, Jabbour, Salma K., Roy, Jason A., Strom, Brian L.

“…Purpose Non‐infectious pneumonitis (NIP) is a common complication of treatments for lung cancer. We know of no existing validated algorithm for identifying NIP…”
Get full text

Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma by Portal, Daniella E., Weiss, Robert E., Wojtowicz, Malgorzata, Mansour, Amal, Monken, Claude, Mehnert, Janice M., Aisner, Joseph A., Kane, Michael, Nishioka, Jennifer, Aisner, Seena, Peters, Stephen, Stein, Mark N., Kim, Isaac Y., Mayer, Tina M., Shih, Weichung, Gulley, James, Streicher, Howard, Singer, Eric A., Lattime, Edmund C.

“…Intravesical BCG is a highly effective treatment for high-grade nonmuscle invasive bladder cancer and carcinoma in situ (CIS); however, for patients who are…”
Get full text

Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF in patients with bladder carcinoma by Portal, Daniella E, Weiss, Robert E, Wojtowicz, Malgorzata, Mansour, Amal, Monken, Claude, Mehnert, Janice M, Aisner, Joseph A

“…Intravesical BCG is a highly effective treatment for high-grade nonmuscle invasive bladder cancer and carcinoma in situ (CIS); however, for patients who are…”
Get full text

A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors by Chan, Nancy, Portal, Daniella E., Moss, Rebecca Anne, Silk, Ann W., Stein, Mark N., Aisner, Joseph, Malhotra, Jyoti, Shih, Weichung, Lin, Hongxia, Kane, Michael P., Mehnert, Janice M., Tan, Antoinette R.

“…Abstract only 3021 Background: Pazopanib (pazo) is an oral tyrosine kinase inhibitor of VEGFR, PDGFR and c-Kit. It is a weak inhibitor of CYP3A4 and CYP2C8 and…”
Get full text